The first dedicated fund for autism innovation.

Investing in life science breakthroughs & therapeutics, digital health, education, and life beyond childhood

Concentrating capital, expertise, and community to accelerate advances in autism. 

Autism affects 1 in 54 American children.

Half have serious comorbidities.

Investments in research, products and services

remain fragmented and often redundant.



Andrea Cunningham

Best-selling author and Marketing Strategist

Venture Capitalist

Emergence, Moai Capital

Venture Capitalist

NEA, Forbes Midas List


Tom Insel, MD

Former Director, Co-founder Mindstrong, NIMH for 13 years


Mike Snyder

Chair of Genomics and Personalized Medicine, Stanford University School of Medicine

Ginnie Breen

Sprout Group 20+ years private equity investor

Bold strategy + Biology + Technology = Audacious goal achieved.